BAR (BAR) 24-hour volatility reaches 48.0%, abnormal buying volume drives sharp fluctuations
Bitget Pulse2026/05/07 19:24Volatility Overview
In the past 24 hours, BAR price rebounded from a low of $0.331 to a high of $0.490, currently quoted at $0.405, with a fluctuation range of 48.0%. This token is actively traded, and Finora AI monitoring detected a 9.3x abnormal buy volume, accompanied by short-term price fluctuations in the $0.431–$0.464 range.
Brief Analysis of the Reasons for the Price Movement
- 9.3x Abnormal Buy Volume: According to Finora AI’s report, buy volume surged 9.3 times in the last 24 hours, with all indicators signaling bullish sentiment. This drove the price to rebound from recent lows, but comes with potential retracement risks.
- Liquidity Sweeps and Order Block Rejection: After previously dropping from a $0.582 high to a $0.419 ATL, signs of liquidity grabbing have recently appeared, triggering a short-term rebound.
Market View and Outlook
The mainstream community sentiment remains cautiously optimistic. Traders emphasize “patience and structure over FOMO,” expecting a short-term retracement to the $0.431–$0.437 support area before rebounding, with targets at $0.453–$0.457. A drop below $0.429 is seen as a stop-loss trigger, likely a stop-loss hunt rather than real accumulation. Risk Alert: High leverage and volatility—wait for confirmation signals.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for information only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.
Australian Dollar crumbles as job losses shatter RBA rate hike hopes
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.
Crypto prices
More
